Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
Before applying any peptide protocol, understand the mechanism it targets and the stage of miniaturisation where it's most effective. Early-stage androgenetic alopecia (Norwood I–III) responds better to stem cell activators; adva…
BPC-157 Upregulates VEGF and FGF receptors; accelerates collagen synthesis Tendons, ligaments, GI lining 250–500mcg twice daily, subcutaneous Structural changes visible in 10–14 days Most direct evidence for soft tissue repair—es…
BPC-157 VEGF upregulation, angiogenesis, fibroblast migration to injury sites 250–500 mcg/day subcutaneous injection 7–14 days (pain reduction); 4–6 weeks (functional improvement) Animal studies robust; human data limited to case…
Primary Mechanism Inhibits S. aureus biofilm, reduces bacterial load by 85–90% within 14 days Stimulates TGF-β and collagen synthesis, increases ceramide production by 34% Suppresses inflammatory cytokine release, reduces visible…
BPC-157 VEGF upregulation, anti-inflammatory cytokine modulation, fibroblast migration Inflammatory phase (weeks 0–6) 250–500mcg daily Subcutaneous (local or systemic) Animal models + case series (no RCTs) Strongest anti-inflamma…
Before comparing specific compounds, understand that peptide selection should align with the phase of healing and the specific tissue systems involved. Knee replacement surgery disrupts bone, cartilage, synovial membrane, ligamen…
Before reviewing individual peptide mechanisms, understand that research applications differ fundamentally from therapeutic use. The table below compares investigational compounds studied in laboratory models. Not approved treatm…
GHK-Cu (Copper Tripeptide) Stimulates dermal papilla proliferation, increases VEGF expression Topical (requires <500 Da molecular weight formulation) Strong. 6/8 RCTs positive, mean 12–17% density increase at 12–16 weeks 1.0–1.5m…
BPC-157 Anti-inflammatory, VEGF upregulation, dopamine D2 receptor modulation Indirect. Normalizes receptor expression in dopamine blockade models Subcutaneous injection (250–500 mcg daily) Preclinical only. Rodent catalepsy mode…
BPC-157 VEGF upregulation, collagen synthesis 250–500 mcg/day Daily (subcutaneous, injury-proximal) 7–10 days for inflammation reduction Best for localized tendon repair. Direct angiogenic effect TB-500 Actin regulation, fibrobla…
BPC-157 Promotes angiogenesis and VEGF expression at injury sites Acute tendon/ligament tears, localized joint inflammation 250–500 mcg daily, split into 2 doses 5–10 days for pain reduction, 3–4 weeks for structural healing Gold…
Different cancer research models require distinct dosing routes, peptide formulations, and timing protocols. Here's how they compare: In Vitro Cell Culture (2D/3D) Direct media addition 1–100 µM depending on target Bacteriostatic…
PT-141 (Bremelanotide) Melanocortin-3 and Melanocortin-4 receptor agonist in hypothalamus. Directly increases sexual arousal independent of testosterone 30–60 minutes subcutaneous 4–6 hours 0.75–2.0mg subcutaneous 45 minutes befo…
Here's how the three best peptides for eczema differ in mechanism, administration, and clinical evidence: KPV Inhibits NF-κB transcription factor via IKK-β blockade Topical (1–5mg/mL) or subcutaneous Phase 2 human trials (open-la…
Glutathione (GSH) is the primary intracellular antioxidant and the rate-limiting cofactor for Phase II detoxification enzymes, including glutathione S-transferases (GSTs) that conjugate heavy metals for biliary and renal excretio…
Bremelanotide (PT-141) MC3R/MC4R agonist. Increases hypothalamic dopamine and arousal signaling Subcutaneous injection (1.75mg) FDA-approved for HSDD; Phase 3 RCT data 40% experience nausea in first 2 doses; requires 45-min pre-a…
Here's the honest answer: oral 'mitochondrial support' supplements sold as CoQ10, PQQ, or NAD+ precursors don't restore mitochondrial function the way research peptides do. Not even close. CoQ10 improves electron transport chain …
This table compares peptide application methods, showing realistic timelines and outcomes for different scar types. Topical serum (daily) GHK-Cu or Matrixyl Shallow rolling scars only 16–24 weeks No Works only if formulation incl…
The table below compares the three peptide classes with the strongest preclinical and clinical evidence for mitochondrial restoration. Each acts through a distinct mechanism, making combination protocols more effective than monot…
BPC-157 FAK-paxillin pathway activation → fibroblast migration + VEGF upregulation for angiogenesis 250–500mcg daily subcutaneous, localized injection near injury site, 4–6 week cycle Moderate. Animal models show 42% faster tendo…